Most of the 150 U.S. medical schools are failing when it comes to building strong conflict of interest policies to limit pharmaceutical marketing on campus, according to the American Medical Student Association (AMSA) PharmFree Scorecard released today. Only seven institutions received 'A's for their conflict of interest policies.

“The schools that earned ‘A’ and ‘B’ scores are to be commended for setting a high bar and aggressively moving forward to ensure medical education, training and patient care is free of commercial bias,” says RxP executive director Robert Restuccia. “While we still have a long way to go, we are optimistic that the growing momentum for reform will change the landscape and there will be great improvement next year.”

To check out the Scorecard, go to